Pharmaceuticals News and Research

RSS

Hatch-Waxman patent infringement litigation concerning Duac Gel dismissed

Perrigo Company announced today that the Hatch-Waxman litigation relating to Duac® Gel (clindamycin phosphate (1%) and benzoyl peroxide (5%) gel) filed by the Stiefel Laboratories division of Glaxo SmithKline has been dismissed with prejudice.

19 Oct 2009

AccuVein signs five-year agreement with the Ferrer Group

AccuVein LLC today announced a five-year agreement with the Ferrer Group, a leading international pharmaceutical and medical devices distribution company, providing the AccuVein AV300, the world's first hand-held, non-contact vein illumination device, to customers in Greece, Spain and Portugal.

19 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for FORTESTA(TM) (testosterone) 2% Gel for men diagnosed with low testosterone (Low T), also known as hypogonadism.

19 Oct 2009

CSC's HealthSpace Advisor selected by GHHS to optimize revenue generation

CSC today announced that the Georgia Hospital Health Services (GHHS), a subsidiary of the Georgia Hospital Association (GHA), has selected CSC's HealthSpace Advisor, a Web-based benchmarking tool introduced earlier this year, to help member hospitals analyze how effectively they use space in key revenue generating areas.

19 Oct 2009

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

19 Oct 2009

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Ardea Biosciences, Inc. announced additional positive results from the completed first cohort of an ongoing Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout.

19 Oct 2009

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

19 Oct 2009

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

19 Oct 2009

IAVI and Ragon Institute sign MOU to devise new vaccine strategies for AIDS

The International AIDS Vaccine Initiative (IAVI) announced today that it has signed a memorandum of understanding with the Ragon Institute to accelerate the development of new and promising AIDS vaccine candidates for testing.

19 Oct 2009

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

Pfizer Inc today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets.

19 Oct 2009

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept(10 mg).

19 Oct 2009

Lobbying efforts heat up on health care

All sorts of special interest groups are stepping up lobbying efforts and spending millions to shape health legislation.

19 Oct 2009

Exposure to online media increases treatment's awareness and favorability: Study

comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today released results from its third annual study Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry, which found that exposure to online media, including a brand's website and online ads, had a significant positive lift on a treatment's awareness and favorability.

19 Oct 2009

NTNU launches European Palliative Care Research Centre

A first-ever pan-European centre devoted to improving patient palliative care and end of life care was officially launched Thursday, October 15, at the Norwegian University of Science and Technology (NTNU) ,with the opening of the European Palliative Care Research Centre.

19 Oct 2009

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Agence France-Presse examines Adjegounle, the "drugs" district in Benin. Although some are able to support their families by selling drugs at "street pharmacies," a minimum of "250 deaths and 340 cases of chronic illnesses linked to such drugs were recorded between April 2007 and June 2008," according to a medical thesis, the news service writes.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

Cannabis Science Inc., an emerging pharmaceutical cannabis company, notes a report by epidemiologists at the Centers for Disease Control and Prevention (CDC) saying that, among people hospitalized with severe cases of the pandemic strain of H1N1 Swine Flu, asthma is by far the most common underlying condition associated with he disease.

19 Oct 2009

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

CK Life Sciences Int'l., (Holdings) Inc. ("CKLS") of Hong Kong (Hong Kong Stock Exchange Limited Stock Code 0775) and WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that CKLS has acquired an additional 116,852,062 restricted voting shares of WEX to bring its holding to 133,179,334 restricted voting shares, or 75.25% of the total outstanding restricted voting shares.

19 Oct 2009

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).

19 Oct 2009

Pharmaceuticals News and Research

Hatch-Waxman patent infringement litigation concerning Duac Gel dismissed

AccuVein signs five-year agreement with the Ferrer Group

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Update from Endo Pharmaceuticals regarding its New Drug Application for FORTESTA

CSC's HealthSpace Advisor selected by GHHS to optimize revenue generation

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Ardea Biosciences reports results of RDEA594 Phase 2a study for hyperuricemia and gout

Phase 3 clinical trial of macimorelin (AEZS-130) to be completed by AEterna Zentaris

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

IAVI and Ragon Institute sign MOU to devise new vaccine strategies for AIDS

Pfizer announces it has combined operations with Wyeth following the closing of the acquisition

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

Lobbying efforts heat up on health care

Exposure to online media increases treatment's awareness and favorability: Study

NTNU launches European Palliative Care Research Centre

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Asthma is the most common underlying condition associated with H1N1 Swine Flu: CDC Report

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring